58-acre South Wicklow farm snapped up pre-auction
Located just 1.7km from the village of Knockananna and 11km from Tinahely, the holding was close to the border with Carlow and Wexford, with a public road running through it.
The farm was due to be offered in four lots, with David Quinn of Gorey-based auctioneers Quinn Property, describing it as a 'valuable parcel of land' which enjoyed 'an excellent location along the L2004'.
The property is in grass with parts of rough grazing and suitable for a number of agricultural uses, with easily accessible fields ideal for grazing or tillage.
Prior to the auction, the farm was guiding in the region of €350,000 (€6,000/acre). With such substantial acreage as this, it is unsurprising that the interest pre-auction would be significant.
'There was a nice bit of interest in the property,' Mr Quinn said afterwards, without disclosing what the final price agreed was. He did say, however, it was in excess of the guide price.
Read More
45-acre Waterford land parcel priced at €500,000
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Agriland
2 hours ago
- Agriland
EU funds development of AI-powered platform for sustainable potato farming
Research continues apace to make greater use of artificial intelligence (AI) within the European potato sector. The driver here is the development of new, regenerative management systems that will, amongst other things, reduce the use of fungicide chemistries to control blight. A case in point is the allocation of £700,000 support funding through the European Commission's European Institute of Innovation and Technology (EIT) Food Innovation Agency to the UK-based agritech company Cropin. The work will entail using real-time field data, computer models, and predictive analytics to secure objective data points that can be used to verify the effects of regenerative methods without compromising potato crop yield or quality, including the dry matter content sought by processors. Known as 'FIRST Potato - Field Intelligence for Regenerative Agriculture and Sustainability in Potato Farming', Cropin's AI-powered initiative is designed to encourage the adoption of regenerative practices across Europe. It brings together a consortium of food processors, research institutions, and sustainability leaders to accelerate the transition from conventional to regenerative practice. Krishna Kumar, CEO and founder of Cropin said: "As regenerative agriculture gains momentum, the absence of verifiable, measurable outcomes poses a real challenge to meaningful, scalable impact. "Without robust digital systems, farmers struggle to consistently uphold regenerative principles. 'Through AI, data intelligence, and real-time decision-support, we are bridging this critical gap, bringing precision, accountability, and scale to regenerative agriculture.' The AI-powered technology will pull together data from sensors, satellite imagery, weather stations, and internet devices to deliver plot-specific daily advisories to growers, tailored to soil profile and microclimatic conditions. The technology is intended to optimise irrigation, input usage and residue management to help farmers manage optimal yield, reduced inputs, and the consistency in quality demanded by processors of crisps and chips. Looking to the future, regenerative crop management practices should be able to meet these demands. However, evidence shows yields can fall in the early years of transition. This is where the AI technology will assist farmers in optimising production. According to Cropin, initially, the scientific validation of the AI platform will be carried out on farms in Denmark, where Cropin has partnered with Aarhus University, a globally recognised leader in sustainable agriculture research. However, the first commercial pilots will involve a UK potato processor, with a second to follow in Germany. "This deployment will deliver collective benefits," Kumar explained. "Growers enhance their profitability, brands meet their sustainability targets, and regenerative practices benefit the planet: it's a win-win for the entire agri-food ecosystem."
The Journal
4 hours ago
- The Journal
The millionaire millennial seeking the presidency: How did Gareth Sheridan get so rich?
BUSINESSMAN GARETH SHERIDAN is seeking to become the youngest-ever Irish presidential candidate during this year's election, and claims to have secured support to make that possible. Much of the Irish public were introduced to 35-year-old Sheridan for the first time this week as a millionaire, pharmaceutical tycoon who recently returned to Ireland having spent the last seven years building up his company in the US. But how, exactly, did he earn his millions? And what does his company do? Acquisitions and mergers Nurtiband, a US-based healthcare-led company valued at approximately $80m, was started by Sheridan in 2012, during his final year at DIT in Dublin, where he was studying businesses and management. Taking inspiration from a transdermal patch his father had for a heart condition, Sheridan wrote his undergraduate thesis on providing properly-dosed medicine to patients through more accessible means, like patches, which are less likely to abuse. Early social media posts from Sheridan show that the company began by selling supplements, such as energy and metabolism-boosting patches, but the Dubliner wanted to branch out into the opioid market. Former Áras contender Seán Gallagher was later enlisted as the company's President (he has since left and has no current relationship with Sheridan) as the CEO worked towards getting the company listed on the Nasdaq stock exchange. Nutriband's strategy focused on carrying out a number of mergers and acquisitions, purchasing companies through its own stock options as a private company, over the last ten years, Sheridan explained on The Entrepreneur Experiment podcast in April. Sheridan focused on merging with firms with existing specialities in pharmaceuticals and biotechnology. It listed on the New York-based stock exchanged in October 2023, generating over $6m on its first day. Nutriband has now focused wholly on opioids through transdermal patches – similar to products used for nicotine-replacement therapy. Opioids, a type of pain-relief medication, have proven to be addictive among some patients. While they are an effective method to treat chronic pain, doctors – particularly in the US – have been reluctant to prescribe the medicines. Image posted by Sheridan in 2023 after his company was listed on the Nasdaq stock exchange in New York. Gareth Sheridan Gareth Sheridan As a result, more people have sought to purchase opioids illegally, and the black market drugs trade responded by introducing potent or synthetic alternatives over the last decade. The most-famous of these in the US is fentanyl, currently. Sheridan said that the most-important of Nutriband's acquisitions was the purchase of 4P Therapeutics in 2018, a company from two pharma veterans who created AVERSA technology , which prevents the misuse of opioids. It is today his lead product. During one acquisition, Nutriband pulled out of purchasing the manufacturer of transdermal patches . It was subsequently reported that a lawyer representing the firm did not disclose their ownership position in both companies. Asked about this on RTÉ Radio One yesterday, Sheridan explained that it was the only time that his firm had faced any trouble with US authorities and that, for Nutriband, it was seen as a minor issue and required the firm to correct submitted paperwork. Advertisement Unique selling point Sheridan has said he wants Nutriband to benefit those who are ill, developing patches that provide patients with a safe dose of medicines that are commonly abused – primarily opioids – targeting those who are in need of the controversial medicines. If abused, the drugs can cause long-term health complications, impact organ health and – in the case of synthetic and potent alternatives especially – minor doses can result in death. We're up and running! Excited to have announced my intention to seek a nomination for the upcoming Presidential election. I look forward to setting out my values and vision for the Presidency over the coming days and continuing to engage with Councillors across the country. — Gareth Sheridan (@GPSheridan1) August 11, 2025 Sheridan's business case is that there are still many people, in the US particularly, who need these pain medicines for proper health-related reasons. He believes the managed doses from his firm's patches is a unique selling point and a prevention of abuse and addiction. He said that there's been an increase of American patients being told to use over-the-counter pain medication for illnesses, and claims his patches could be a safer and more appropriate option. Pharmaceutical patches Sheridan in April said acquisitions and mergers were 'the strategy' for the company. Some of the previous owners from the purchased companies went on to join Sheridan and held positions at Nutriband for a short time. He explained, due to his own lack of expertise in pharmacology, he needed those who could help actually develop his ideas. He added: 'It also kept us away from expensive money. I am able to retain today a good proportion of the company because we didn't do angel [investor] rounds, seed rounds. We didn't do the traditional route.' News reports of the company's activities recently have focused on its newest patch, which would deliver a proper prescribed dose of fentanyl . The firm is still in ongoing discussions with the US's drugs regulator, the Food and Drug Administration. In preparation for its approval, it has offered shareholders particular stock options to raise funds. Success? Nutriband is yet to generate any revenue. In its most-recent public quarterly report, at the end of October last year, it recorded a net-loss of $1.3m. Speaking to The Entrepreneur Experiment in April, Sheridan said: 'In most public companies it's either one person makes a million dollars or, years later, dozens of people make multiple millions of dollars. So there's patience and trust involved.' The Áras hopeful, who has stepped back as CEO from Nutriband to pursuit the election later this year, said he is certain the company will be worth a billion dollars in the future. Sheridan said the firm has been careful not to waste any funding too: 'We've been very careful not to raise money that we don't need – money that is sitting in a bank account at the expense of shareholders [...] It's just little things like that.' He told RTÉ Radio One yesterday that he believes Nutriband will still achieve that goal, with or without him. He said that he intends to have a stake in the firm, should he be placed on the ballot and elected President. Sheridan said he is seeking to be nominated as a candidate to represent the interests of young people who feel that they must emigrate for work and other opportunities due to the housing situation here. He is due to announced his platform's values later this week. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Irish Examiner
7 hours ago
- Irish Examiner
Analog Devices' Limerick unit pays out dividends of $5.42bn
The main Irish arm of semiconductor manufacturer Analog Devices has paid out combined dividends of $5.42bn (€4.67bn) this year and in 2024. New accounts show that the Limerick-based Analog Devices International UC has paid out the dividends as profits decreased by 72% to $487.78m in the 12 months to the end of November 2, 2024. The drop in profits arose mainly from non-cash amortisation costs rising from $2.04bn to $2.73bn. Revenues at the firm increased by 4% from $8.18bn to $8.55bn during the 12-month period. In May 2023, the firm announced plans to build a €630m facility in Co Limerick, adding 600 jobs to its Irish workforce. The investment at its European regional headquarters in the Raheen Business Park involved the construction of a 45,000sq ft research, development, and manufacturing facility. The directors said the results for 2024 'were in line with expectations'. They said dividends of $3.18bn were paid during 2024 and in a post-balance sheet event the company paid further dividends of $2.247bn to Analog Devices Limerick UC. Numbers employed increased by 131 from 1,626 to 1,757 during 2024. Staff was made up of 741 in manufacturing, 634 in engineering, 308 in marketing and 74 in administration as staff costs marginally increased to $195.77m. The directors said gross margin decreased primarily as a result of a change in product mix. They said the operating profit has decreased due mainly to the $695.9m increase in the amortisation of intangible assets while there was also an increase in distribution and administrative expenses of $388m to $1.83bn. The company recorded post-tax profits of $398.7m after incurring a corporation tax charge of $89m. Sounding an upbeat note, the directors said: 'Our diversified business model combined with our leading technology portfolio position the company to deliver sustainable long-term growth in the years ahead'. The directors said the company has a purpose-built European Research and Development Building at their Limerick campus and the R&D spend last year totalled $1bn - up from a spend of $615.2m in 2023 on the design, development and improvement of new and existing products and manufacturing processes. Directors' pay totalled $2.19m made up of emoluments of $715,000, $1.42m on a long-term incentive scheme and $54,000 in pension contributions. At the end of December, the firm had shareholder funds of $26.74bn. The company's cash funds increased from €163m to €570.73m.
